Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Cash from Operations (2019 - 2025)

Historic Cash from Operations for Benitec Biopharma (BNTC) over the last 7 years, with Q2 2025 value amounting to -$8.2 million.

  • Benitec Biopharma's Cash from Operations fell 14977.22% to -$8.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$23.6 million, marking a year-over-year decrease of 2163.07%. This contributed to the annual value of -$23.6 million for FY2025, which is 2163.07% down from last year.
  • As of Q2 2025, Benitec Biopharma's Cash from Operations stood at -$8.2 million, which was down 14977.22% from -$3.1 million recorded in Q1 2025.
  • In the past 5 years, Benitec Biopharma's Cash from Operations registered a high of -$2.0 million during Q1 2021, and its lowest value of -$8.2 million during Q2 2025.
  • For the 5-year period, Benitec Biopharma's Cash from Operations averaged around -$4.7 million, with its median value being -$4.4 million (2021).
  • Per our database at Business Quant, Benitec Biopharma's Cash from Operations tumbled by 16007.8% in 2021 and then surged by 5014.59% in 2025.
  • Benitec Biopharma's Cash from Operations (Quarter) stood at -$3.3 million in 2021, then crashed by 76.25% to -$5.9 million in 2022, then rose by 8.76% to -$5.3 million in 2023, then crashed by 44.14% to -$7.7 million in 2024, then decreased by 6.82% to -$8.2 million in 2025.
  • Its last three reported values are -$8.2 million in Q2 2025, -$3.1 million for Q1 2025, and -$7.7 million during Q4 2024.